GXO Reports Fourth Quarter and Full Year 2024 Results

Delivered record revenue for both Q4 and full year 2024Organic revenue growth accelerated sequentially each quarter in 2024Closed more than $1 billion of new business wins for the second consecutive year; won largest-ever contract, of $2.5 billion lifetime value, in health sciencesAnnounced 2025 guidance: Organic revenue growth of 3% - 6%Adjusted EBITDA of $840 million - $860 millionAdjusted diluted EPS of $2.40 - $2.60Adjusted EBITDA to free cash flow conversion of 25% to 35% GREENWICH, Conn., Feb. 12, 20 ...